{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:54Z","timestamp":1781650674162,"version":"3.54.5"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC 2021-00215"],"award-info":[{"award-number":["CRC 2021-00215"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bluetongue (BT) is a severe arboviral disease affecting sheep, cows, and other wild ruminants, caused by the Bluetongue virus (BTV). The virus has evolved into over 32 serotypes, rendering existing vaccines less effective. While the structural proteins of this virus represent promising targets for vaccine development, they unfortunately exhibit high amino acid polymorphism and are laden with numerous inhibitory epitopes. However, certain structural proteins such as VP1 and VP7 are highly conserved and may contain epitopes capable of triggering cross-reactive cell-mediated immunity (CMI). In this study, we identified highly conserved MHC-I and -II-restricted T cell epitopes within VP1, VP5, and VP7 BTV proteins and designed multiepitope vaccine constructs using an in silico immunoinformatics pipeline for both laboratory mouse and bovine natural systems. The conserved epitopes utilized in the vaccines are highly antigenic, non-allergenic, non-toxic, and predicted to be capable of inducing IFN-\ud835\udefe. Both mouse and bovine vaccines were tethered with Toll-like receptor (TLR)-4-agonist adjuvants, beta-defensin 2\u201350\u00a0S ribosomal unit to stimulate innate immunity for the CMI development. Protein-protein docking analysis suggested favorable binding affinities between the vaccine constructs and TLR4, while 100-nanosecond molecular dynamics simulations supported the structural stability of the complexes. Although these computational findings are promising, all results require experimental validation. Future in vitro and in vivo studies are essential to confirm the immunogenicity, safety, and protective efficacy of the proposed vaccine candidates in target species.<\/jats:p>","DOI":"10.1186\/s12864-025-12294-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:28:49Z","timestamp":1776756529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unleashing the immune arsenal: development of broad spectrum multiepitope bluetongue vaccine targeting conserved T cell epitopes of structural proteins"],"prefix":"10.1186","volume":"27","author":[{"given":"Harish Babu","family":"Kolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa Hebbandi","family":"Nanjundappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Paul Clement","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kelvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channakeshava Sokke","family":"Umeshappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"12294_CR1","doi-asserted-by":"crossref","unstructured":"Matthijnssens J, Attoui H, B\u00e1nyai K, Brussaard CPD, Danthi P, Del Vas M, Dermody TS, Duncan R, F\u0101ng \u65b9\u52e4 Q, Johne R, Mertens PPC, Jaafar M, Patton F, \u7b39\u8c37\u5b5d\u82f1 JTS, \u9234\u6728\u4fe1\u5f18 TS, N., Wei \u9b4f\u592a\u4e91 T. ICTV virus taxonomy profile: sedoreoviridae 2022. J Gen Virol 2022, 103(10).","DOI":"10.1099\/jgv.0.001782"},{"issue":"4","key":"12294_CR2","first-page":"426","volume":"40","author":"PP Mertens","year":"2004","unstructured":"Mertens PP, Diprose J, Maan S, Singh KP, Attoui H, Samuel AR. Bluetongue virus replication, molecular and structural biology. Vet Ital. 2004;40(4):426\u201337.","journal-title":"Vet Ital"},{"issue":"Pt2","key":"12294_CR3","first-page":"621","volume":"88","author":"NS Maan","year":"2012","unstructured":"Maan NS, Maan S, Nomikou K, Guimera M, Pullinger G, Singh KP, Belaganahalli MN, Mertens PP. The genome sequence of bluetongue virus type 2 from india: evidence for reassortment between Eastern and Western topotype field strains. J Gen Virol. 2012;88(Pt2):621\u201330.","journal-title":"J Gen Virol"},{"issue":"4","key":"12294_CR4","first-page":"185","volume":"39","author":"DW Verwoerd","year":"1972","unstructured":"Verwoerd DW, Huismans H. Studies on the in vitro and the in vivo transcription of the bluetongue virus genome. Onderstepoort J Vet Res. 1972;39(4):185\u201391.","journal-title":"Onderstepoort J Vet Res"},{"issue":"3\u20134","key":"12294_CR5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2011.03.005","volume":"141","author":"CS Umeshappa","year":"2011","unstructured":"Umeshappa CS, Singh KP, Channappanavar R, Sharma K, Nanjundappa RH, Saxena M, Singh R, Sharma AK. A comparison of intradermal and intravenous inoculation of bluetongue virus serotype 23 in sheep for clinico-pathology, and viral and immune responses. Vet Immunol Immunopathol. 2011;141(3\u20134):230\u20138.","journal-title":"Vet Immunol Immunopathol"},{"issue":"3\u20134","key":"12294_CR6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0147-9571(94)90043-4","volume":"17","author":"NJ MacLachlan","year":"1994","unstructured":"MacLachlan NJ. The pathogenesis and immunology of bluetongue virus infection of ruminants. Comp Immunol Microbiol Infect Dis. 1994;17(3\u20134):197\u2013206.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"11","key":"12294_CR7","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/pathogens10111528","volume":"10","author":"JM Rojas","year":"2021","unstructured":"Rojas JM, Mart\u00edn V, Sevilla N. Vaccination as a strategy to prevent bluetongue virus vertical transmission. Pathogens. 2021;10(11):1528.","journal-title":"Pathogens"},{"issue":"2","key":"12294_CR8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/1040841X.2016.1186005","volume":"43","author":"F Feenstra","year":"2017","unstructured":"Feenstra F, van Rijn PA. Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations. Crit Rev Microbiol. 2017;43(2):142\u201355.","journal-title":"Crit Rev Microbiol"},{"key":"12294_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fvets.2019.00407","volume":"6","author":"PA van Rijn","year":"2019","unstructured":"van Rijn PA. Prospects of Next-Generation vaccines for bluetongue. Front Vet Sci. 2019;6:407.","journal-title":"Front Vet Sci"},{"issue":"1","key":"12294_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/tbed.13338","volume":"67","author":"V Bumbarov","year":"2020","unstructured":"Bumbarov V, Golender N, Jenckel M, Wernike K, Beer M, Khinich E, Zalesky O, Erster O. Characterization of bluetongue virus serotype 28. Transbound Emerg Dis. 2020;67(1):171\u201382.","journal-title":"Transbound Emerg Dis"},{"key":"12294_CR11","doi-asserted-by":"crossref","unstructured":"Rojas JM, Martin V, Sevilla N. Vaccination as a strategy to prevent bluetongue virus vertical transmission. Pathogens 2021, 10(11).","DOI":"10.3390\/pathogens10111528"},{"issue":"52","key":"12294_CR12","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2014.10.033","volume":"32","author":"F Feenstra","year":"2014","unstructured":"Feenstra F, Maris-Veldhuis M, Daus FJ, Tacken MG, Moormann RJ, van Gennip RG, van Rijn PA. VP2-serotyped live-attenuated bluetongue virus without NS3\/NS3a expression provides serotype-specific protection and enables DIVA. Vaccine. 2014;32(52):7108\u201314.","journal-title":"Vaccine"},{"issue":"2","key":"12294_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrmicro2052","volume":"7","author":"P Roy","year":"2009","unstructured":"Roy P, Boyce M, Noad R. Prospects for improved bluetongue vaccines. Nat Rev Microbiol. 2009;7(2):120\u20138.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"12294_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/tbed.12004","volume":"61","author":"G Savini","year":"2014","unstructured":"Savini G, Lorusso A, Paladini C, Migliaccio P, Di Gennaro A, Di Provvido A, Scacchia M, Monaco F. Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy. Transbound Emerg Dis. 2014;61(1):69\u201374.","journal-title":"Transbound Emerg Dis"},{"key":"12294_CR15","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.jvacx.2020.100060","volume":"5","author":"TP Monath","year":"2020","unstructured":"Monath TP, Kortekaas J, Watts DM, Christofferson RC, Desiree LaBeaud A, Gowen B, Peters CJ, Smith DR, Swanepoel R, Morrill JC, et al. Theoretical risk of genetic reassortment should not impede development of live, attenuated rift Valley fever (RVF) vaccines commentary on the draft WHO RVF target product profile. Vaccine X. 2020;5:100060.","journal-title":"Vaccine X"},{"issue":"1\u20132","key":"12294_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prevetmed.2011.05.011","volume":"101","author":"S Nusinovici","year":"2011","unstructured":"Nusinovici S, Seegers H, Joly A, Beaudeau F, Fourichon C. A side effect of decreased fertility associated with vaccination against bluetongue virus serotype 8 in Holstein dairy cows. Prev Vet Med. 2011;101(1\u20132):42\u201350.","journal-title":"Prev Vet Med"},{"key":"12294_CR17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","volume":"17","author":"AT Martino","year":"2020","unstructured":"Martino AT, Markusic DM. Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev. 2020;17:198\u2013208.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"12294_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12981-024-00655-y","volume":"21","author":"S Zou","year":"2024","unstructured":"Zou S, Wu M, Ming F, Wu S, Guo W, Marley G, Xing Z, Zhang Z, Zeng M, Sun C, et al. Correction: Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals. AIDS Res Ther. 2024;21(1):63.","journal-title":"AIDS Res Ther"},{"key":"12294_CR19","doi-asserted-by":"crossref","unstructured":"de Perez AC, Sanchez-Cordon PJ, de las Heras AI, Sanchez-Vizcaino JM. Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep. ScientificWorldJournal 2012, 2012:147158.","DOI":"10.1100\/2012\/147158"},{"key":"12294_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.vaccine.2009.10.027","volume":"28","author":"E Calvo-Pinilla","year":"2009","unstructured":"Calvo-Pinilla E, R-CT, Sevilla N. Heterologous prime boost vaccination with DNA and Recombinant modified vaccinia virus Ankara protects IFNAR(\u2013\/\u2013) mice against lethal bluetongue infection. Vaccine. 2009;28:437\u201345.","journal-title":"Vaccine"},{"key":"12294_CR21","doi-asserted-by":"crossref","unstructured":"Jabbar TKC-PE, Mateos F, Gubbins S, Bin-Tarif A: Protection of IFNAR (\u2013\/\u2013) Mice against Bluetongue Virus Serotype 8, by, Heterologous. (DNA\/rMVA) and Homologous (rMVA\/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2. Plos One 2013, 8(4):e60574.","DOI":"10.1371\/journal.pone.0060574"},{"issue":"23","key":"12294_CR22","doi-asserted-by":"crossref","first-page":"168297","DOI":"10.1016\/j.jmb.2023.168297","volume":"435","author":"S Pagliari","year":"2023","unstructured":"Pagliari S, Dema B, Sanchez-Martinez A, Montalvo Zurbia-Flores G, Rollier CS. DNA vaccines: History, molecular mechanisms and future perspectives. J Mol Biol. 2023;435(23):168297.","journal-title":"J Mol Biol"},{"key":"12294_CR23","doi-asserted-by":"crossref","unstructured":"Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PP, Castillo-Olivares J. Protection of IFNAR (\u2013\/\u2013) mice against bluetongue virus serotype 8, by heterologous (DNA\/rMVA) and homologous (rMVA\/rMVA) Vaccination, expressing Outer-Capsid protein VP2. PLoS ONE. 2013;8(4):e60574.","DOI":"10.1371\/journal.pone.0060574"},{"key":"12294_CR24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.11.013","volume":"182","author":"E Calvo-Pinilla","year":"2014","unstructured":"Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marin-Lopez A. Recombinant vaccines against bluetongue virus. Virus Res. 2014;182:78\u201386.","journal-title":"Virus Res"},{"key":"12294_CR25","doi-asserted-by":"crossref","unstructured":"Kozak M, Hu J. DNA vaccines: their Formulations, engineering and delivery. Vaccines (Basel) 2024, 12(1).","DOI":"10.3390\/vaccines12010071"},{"key":"12294_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vetmic.2017.03.015","volume":"206","author":"C Mayo","year":"2017","unstructured":"Mayo C, Lee J, Kopanke J, MacLachlan NJ. A review of potential bluetongue virus vaccine strategies. Vet Microbiol. 2017;206:84\u201390.","journal-title":"Vet Microbiol"},{"issue":"1","key":"12294_CR27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8(1):149.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"12294_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010;8(1):62\u201373.","journal-title":"Nat Rev Microbiol"},{"key":"12294_CR29","doi-asserted-by":"crossref","unstructured":"Tang J, Amin MA, Campian JL. Past, Present, and future of viral vector vaccine platforms: A comprehensive review. Vaccines (Basel) 2025, 13(5).","DOI":"10.3390\/vaccines13050524"},{"issue":"5","key":"12294_CR30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10875-019-00653-0","volume":"39","author":"L Poyhonen","year":"2019","unstructured":"Poyhonen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Correction to: Life-Threatening infections due to Live-Attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(5):527.","journal-title":"J Clin Immunol"},{"key":"12294_CR31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","volume":"479\u2013480","author":"PD Minor","year":"2015","unstructured":"Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479\u2013480:379\u201392.","journal-title":"Virology"},{"issue":"6","key":"12294_CR32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","volume":"28","author":"AS Lauring","year":"2010","unstructured":"Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010;28(6):573\u20139.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"12294_CR33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0264-410X(94)90289-5","volume":"12","author":"P Roy","year":"1994","unstructured":"Roy P, Bishop DH, LeBlois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine. 1994;12(9):805\u201311.","journal-title":"Vaccine"},{"issue":"3","key":"12294_CR34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.vaccine.2012.11.016","volume":"31","author":"M Stewart","year":"2013","unstructured":"Stewart M, Dubois E, Sailleau C, Breard E, Viarouge C, Desprat A, Thiery R, Zientara S, Roy P. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen. Vaccine. 2013;31(3):553\u20138.","journal-title":"Vaccine"},{"key":"12294_CR35","doi-asserted-by":"crossref","first-page":"1502484","DOI":"10.3389\/fimmu.2025.1502484","volume":"16","author":"LN Anderson","year":"2025","unstructured":"Anderson LN, Hoyt CT, Zucker JD, McNaughton AD, Teuton JR, Karis K, Arokium-Christian NN, Warley JT, Stromberg ZR, Gyori BM, et al. Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions. Front Immunol. 2025;16:1502484.","journal-title":"Front Immunol"},{"key":"12294_CR36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.addr.2021.02.004","volume":"172","author":"W Hwang","year":"2021","unstructured":"Hwang W, Lei W, Katritsis NM, MacMahon M, Chapman K, Han N. Current and prospective computational approaches and challenges for developing COVID-19 vaccines. Adv Drug Deliv Rev. 2021;172:249\u201374.","journal-title":"Adv Drug Deliv Rev"},{"key":"12294_CR37","doi-asserted-by":"crossref","unstructured":"Wei Y, Qiu T, Ai Y, Zhang Y, Xie J, Zhang D, Luo X, Sun X, Wang X, Qiu J. Advances of computational methods enhance the development of multi-epitope vaccines. Brief Bioinform 2024, 26(1).","DOI":"10.1093\/bib\/bbaf055"},{"issue":"21","key":"12294_CR38","doi-asserted-by":"crossref","first-page":"e39433","DOI":"10.1016\/j.heliyon.2024.e39433","volume":"10","author":"Z Azami","year":"2024","unstructured":"Azami Z, Farahmand M, Kavousi M. A new multi-epitope DNA vaccine against Helicobacter pylori infection in a BALB\/c mouse model. Heliyon. 2024;10(21):e39433.","journal-title":"Heliyon"},{"key":"12294_CR39","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3389\/fmicb.2017.01805","volume":"8","author":"L Babu","year":"2017","unstructured":"Babu L, Uppalapati SR, Sripathy MH, Reddy PN. Evaluation of Recombinant Multi-Epitope outer membrane Protein-Based Klebsiella pneumoniae subunit vaccine in mouse model. Front Microbiol. 2017;8:1805.","journal-title":"Front Microbiol"},{"key":"12294_CR40","doi-asserted-by":"crossref","unstructured":"Guo N, Niu Z, Yan Z, Liu W, Shi L, Li C, Yao Y, Shi L. Immunoinformatics design and in vivo immunogenicity evaluation of a conserved CTL Multi-Epitope vaccine targeting HPV16 E5, E6, and E7 proteins. Vaccines (Basel) 2024, 12(4).","DOI":"10.3390\/vaccines12040392"},{"issue":"1","key":"12294_CR41","doi-asserted-by":"crossref","first-page":"16258","DOI":"10.1038\/s41598-020-73179-w","volume":"10","author":"S Hasanzadeh","year":"2020","unstructured":"Hasanzadeh S, Habibi M, Shokrgozar MA, Ahangari Cohan R, Ahmadi K, Asadi Karam MR, Bouzari S. In Silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli. Sci Rep. 2020;10(1):16258.","journal-title":"Sci Rep"},{"issue":"21\u201322","key":"12294_CR42","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1007\/s00253-021-11609-z","volume":"105","author":"RK Kota","year":"2021","unstructured":"Kota RK, Kolla HB, Reddy PN, Kalagatur NK, Samudrala SK. Immunoinformatics analysis and evaluation of Recombinant chimeric triple antigen toxoid (r-HAB) against Staphylococcus aureus toxaemia in mouse model. Appl Microbiol Biotechnol. 2021;105(21\u201322):8297\u2013311.","journal-title":"Appl Microbiol Biotechnol"},{"key":"12294_CR43","doi-asserted-by":"crossref","first-page":"109999","DOI":"10.1016\/j.intimp.2023.109999","volume":"117","author":"M Rezaei","year":"2023","unstructured":"Rezaei M, Esmaeili F, Reza Asadi Karam M, Ehsani P, Abbasnezhad Farsangi Z, Bouzari S. In Silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with Chitosan nanoparticles against uropathogenic Escherichia coli. Int Immunopharmacol. 2023;117:109999.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12294_CR44","doi-asserted-by":"crossref","first-page":"23121","DOI":"10.1038\/s41598-021-01770-w","volume":"11","author":"E Mahdevar","year":"2021","unstructured":"Mahdevar E, Kefayat A, Safavi A, Behnia A, Hejazi SH, Javid A, Ghahremani F. Immunoprotective effect of an in Silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model. Sci Rep. 2021;11(1):23121.","journal-title":"Sci Rep"},{"issue":"2","key":"12294_CR45","doi-asserted-by":"crossref","first-page":"e0010177","DOI":"10.1371\/journal.pntd.0010177","volume":"16","author":"RM Jones Jr","year":"2022","unstructured":"Jones RM Jr., Seo H, Zhang W, Sack DA. A multi-epitope fusion antigen candidate vaccine for enterotoxigenic Escherichia coli is protective against strain B7A colonization in a rabbit model. PLoS Negl Trop Dis. 2022;16(2):e0010177.","journal-title":"PLoS Negl Trop Dis"},{"key":"12294_CR46","doi-asserted-by":"crossref","unstructured":"Silva AJD, de Jesus ALS, Leal LRS, de Macedo LS, da Silva Barros BR, de Sousa GF, da, Paz Leoncio Alves S, Pena LJ, de Melo CML, de Freitas AC. Whole Yeast Vaccine Displaying ZIKV B and T Cell Epitopes Induces Cellular Immune Responses in the Murine Model. Pharmaceutics 2023, 15(7).","DOI":"10.3390\/pharmaceutics15071898"},{"issue":"6","key":"12294_CR47","doi-asserted-by":"crossref","first-page":"e0268251","DOI":"10.1371\/journal.pone.0268251","volume":"17","author":"N Khairkhah","year":"2022","unstructured":"Khairkhah N, Bolhassani A, Agi E, Namvar A, Nikyar A. Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen. PLoS ONE. 2022;17(6):e0268251.","journal-title":"PLoS ONE"},{"issue":"6","key":"12294_CR48","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00425-009-0918-2","volume":"229","author":"RE Soria-Guerra","year":"2009","unstructured":"Soria-Guerra RE, Alpuche-Solis AG, Rosales-Mendoza S, Moreno-Fierros L, Bendik EM, Martinez-Gonzalez L, Korban SS. Expression of a multi-epitope DPT fusion protein in transplastomic tobacco plants retains both antigenicity and immunogenicity of all three components of the functional oligomer. Planta. 2009;229(6):1293\u2013302.","journal-title":"Planta"},{"key":"12294_CR49","doi-asserted-by":"crossref","unstructured":"Li G, Shu J, Jin J, Shu J, Feng H, Chen J, He Y. Development of a Multi-Epitope vaccine for Mycoplasma hyopneumoniae and evaluation of its immune responses in mice and piglets. Int J Mol Sci 2022, 23(14).","DOI":"10.3390\/ijms23147899"},{"issue":"1","key":"12294_CR50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13567-018-0556-4","volume":"49","author":"L Martinelle","year":"2018","unstructured":"Martinelle L, Dal Pozzo F, Thys C, De Leeuw I, Van Campe W, De Clercq K, Thiry E, Saegerman C. Assessment of cross-protection induced by a bluetongue virus (BTV) serotype 8 vaccine towards other BTV serotypes in experimental conditions. Vet Res. 2018;49(1):63.","journal-title":"Vet Res"},{"key":"12294_CR51","doi-asserted-by":"crossref","first-page":"1424307","DOI":"10.3389\/fimmu.2024.1424307","volume":"15","author":"HB Kolla","year":"2024","unstructured":"Kolla HB, Dutt M, Kumar A, Hebbandi Nanjunadappa R, Karakach T, Singh KP, Kelvin D, Clement Mertens PP, Umeshappa CS. Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine. Front Immunol. 2024;15:1424307.","journal-title":"Front Immunol"},{"issue":"3","key":"12294_CR52","doi-asserted-by":"crossref","first-page":"e31911","DOI":"10.1371\/journal.pone.0031911","volume":"7","author":"MN Belaganahalli","year":"2012","unstructured":"Belaganahalli MN, Maan S, Maan NS, Nomikou K, Pritchard I, Lunt R, Kirkland PD, Attoui H, Brownlie J, Mertens PP. Full genome sequencing and genetic characterization of Eubenangee viruses identify Pata virus as a distinct species within the genus orbivirus. PLoS ONE. 2012;7(3):e31911.","journal-title":"PLoS ONE"},{"issue":"4","key":"12294_CR53","doi-asserted-by":"crossref","first-page":"e10323","DOI":"10.1371\/journal.pone.0010323","volume":"5","author":"S Maan","year":"2010","unstructured":"Maan S, Maan NS, van Rijn PA, van Gennip RG, Sanders A, Wright IM, Batten C, Hoffmann B, Eschbaumer M, Oura CA, et al. Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains. PLoS ONE. 2010;5(4):e10323.","journal-title":"PLoS ONE"},{"issue":"1","key":"12294_CR54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-020-00218-y","volume":"5","author":"E Calvo-Pinilla","year":"2020","unstructured":"Calvo-Pinilla E, Marin-Lopez A, Moreno S, Lorenzo G, Utrilla-Trigo S, Jimenez-Cabello L, Benavides J, Nogales A, Blasco R, Brun A, et al. A protective bivalent vaccine against rift Valley fever and bluetongue. NPJ Vaccines. 2020;5(1):70.","journal-title":"NPJ Vaccines"},{"key":"12294_CR55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.antiviral.2014.07.008","volume":"110","author":"A Marin-Lopez","year":"2014","unstructured":"Marin-Lopez A, Otero-Romero I, de la Poza F, Menaya-Vargas R, Calvo-Pinilla E, Benavente J, Martinez-Costas JM, Ortego J. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-\/-) mice. Antiviral Res. 2014;110:42\u201351.","journal-title":"Antiviral Res"},{"issue":"32","key":"12294_CR56","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1016\/j.vaccine.2014.05.056","volume":"32","author":"F Mohd Jaafar","year":"2014","unstructured":"Mohd Jaafar F, Belhouchet M, Vitour D, Adam M, Breard E, Zientara S, Mertens PP, Attoui H. Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect alpha\/beta interferon-receptor knock-out (IFNAR(-\/-)) mice from homologous lethal challenge. Vaccine. 2014;32(32):4059\u201367.","journal-title":"Vaccine"},{"key":"12294_CR57","doi-asserted-by":"crossref","first-page":"645561","DOI":"10.3389\/fvets.2021.645561","volume":"8","author":"JM Rojas","year":"2021","unstructured":"Rojas JM, Barba-Moreno D, Avia M, Sevilla N, Martin V. Vaccination with Recombinant adenoviruses expressing the bluetongue virus subunits VP7 and VP2 provides protection against heterologous virus challenge. Front Vet Sci. 2021;8:645561.","journal-title":"Front Vet Sci"},{"issue":"1","key":"12294_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcpa.2009.04.003","volume":"141","author":"NJ Maclachlan","year":"2009","unstructured":"Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. J Comp Pathol. 2009;141(1):1\u201316.","journal-title":"J Comp Pathol"},{"key":"12294_CR59","first-page":"119","volume":"162","author":"IM Parsonson","year":"1990","unstructured":"Parsonson IM. Pathology and pathogenesis of bluetongue infections. Curr Top Microbiol Immunol. 1990;162:119\u201341.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"D1","key":"12294_CR60","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","volume":"47","author":"R Vita","year":"2019","unstructured":"Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"12294_CR61","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4049\/jimmunol.1501721","volume":"196","author":"T Trolle","year":"2016","unstructured":"Trolle T, McMurtrey CP, Sidney J, Bardet W, Osborn SC, Kaever T, Sette A, Hildebrand WH, Nielsen M, Peters B. The length distribution of class I-Restricted T cell epitopes is determined by both peptide supply and MHC Allele-Specific binding preference. J Immunol. 2016;196(4):1480\u20137.","journal-title":"J Immunol"},{"issue":"5","key":"12294_CR62","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","volume":"12","author":"M Nielsen","year":"2003","unstructured":"Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12(5):1007\u201317.","journal-title":"Protein Sci"},{"issue":"7","key":"12294_CR63","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.4049\/jimmunol.1001006","volume":"185","author":"J Sidney","year":"2010","unstructured":"Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, Sette A. Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. J Immunol. 2010;185(7):4189\u201398.","journal-title":"J Immunol"},{"key":"12294_CR64","doi-asserted-by":"crossref","unstructured":"Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. Jounral of Immunology; 1998.","DOI":"10.4049\/jimmunol.160.7.3363"},{"issue":"W1","key":"12294_CR65","doi-asserted-by":"crossref","first-page":"W502","DOI":"10.1093\/nar\/gkz452","volume":"47","author":"SK Dhanda","year":"2019","unstructured":"Dhanda SK, Mahajan S, Paul S, Yan Z, Kim H, Jespersen MC, Jurtz V, Andreatta M, Greenbaum JA, Marcatili P, et al. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res. 2019;47(W1):W502\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"11\u201312","key":"12294_CR66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00251-015-0877-7","volume":"67","author":"M Pandya","year":"2015","unstructured":"Pandya M, Rasmussen M, Hansen A, Nielsen M, Buus S, Golde W, Barlow J. A modern approach for epitope prediction: identification of foot-and-mouth disease virus peptides binding bovine leukocyte antigen (BoLA) class I molecules. Immunogenetics. 2015;67(11\u201312):691\u2013703.","journal-title":"Immunogenetics"},{"issue":"1\u20132","key":"12294_CR67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.vetimm.2015.06.007","volume":"167","author":"N Svitek","year":"2015","unstructured":"Svitek N, Awino E, Nene V, Steinaa L. BoLA-6*01301 and BoLA-6*01302, two allelic variants of the A18 haplotype, present the same epitope from the Tp1 antigen of theileria Parva. Vet Immunol Immunopathol. 2015;167(1\u20132):80\u20135.","journal-title":"Vet Immunol Immunopathol"},{"key":"12294_CR68","doi-asserted-by":"crossref","unstructured":"Fisch A, Reynisson B, Benedictus L, Nicastri A, Vasoya D, Morrison I, Buus S, Ferreira BR, Kinney Ferreira de Miranda Santos I, Ternette N et al. Integral Use of Immunopeptidomics and Immunoinformatics for the Characterization of Antigen Presentation and Rational Identification of BoLA-DR-Presented Peptides and Epitopes. J Immunol 2021, 206(10):2489\u20132497.","DOI":"10.4049\/jimmunol.2001409"},{"key":"12294_CR69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2105-8-4","volume":"8","author":"IA Doytchinova","year":"2007","unstructured":"Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4.","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"12294_CR70","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1007\/s00894-014-2278-5","volume":"20","author":"I Dimitrov","year":"2014","unstructured":"Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2\u2013a server for in Silico prediction of allergens. J Mol Model. 2014;20(6):2278.","journal-title":"J Mol Model"},{"issue":"Suppl 6","key":"12294_CR71","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1471-2105-14-S6-S4","volume":"14","author":"I Dimitrov","year":"2013","unstructured":"Dimitrov I, Flower DR, Doytchinova I. AllerTOP\u2013a server for in Silico prediction of allergens. BMC Bioinformatics. 2013;14(Suppl 6):S4.","journal-title":"BMC Bioinformatics"},{"issue":"9","key":"12294_CR72","doi-asserted-by":"crossref","first-page":"e73957","DOI":"10.1371\/journal.pone.0073957","volume":"8","author":"S Gupta","year":"2013","unstructured":"Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery C, Raghava GP. In Silico approach for predicting toxicity of peptides and proteins. PLoS ONE. 2013;8(9):e73957.","journal-title":"PLoS ONE"},{"key":"12294_CR73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1745-6150-8-30","volume":"8","author":"SK Dhanda","year":"2013","unstructured":"Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct. 2013;8:30.","journal-title":"Biol Direct"},{"issue":"15","key":"12294_CR74","doi-asserted-by":"crossref","first-page":"e85955","DOI":"10.1172\/jci.insight.85955","volume":"1","author":"K El Bissati","year":"2016","unstructured":"El Bissati K, Chentoufi AA, Krishack PA, Zhou Y, Woods S, Dubey JP, Vang L, Lykins J, Broderick KE, Mui E, et al. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 Transgenic mice against Toxoplasma gondii. JCI Insight. 2016;1(15):e85955.","journal-title":"JCI Insight"},{"issue":"8","key":"12294_CR75","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.4049\/jimmunol.157.8.3242","volume":"157","author":"CC Bergmann","year":"1996","unstructured":"Bergmann CC, Yao Q, Ho CK, Buckwold SL. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol. 1996;157(8):3242\u20139.","journal-title":"J Immunol"},{"issue":"9","key":"12294_CR76","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.4049\/jimmunol.166.9.5366","volume":"166","author":"MP Velders","year":"2001","unstructured":"Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001;166(9):5366\u201373.","journal-title":"J Immunol"},{"issue":"11","key":"12294_CR77","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.4049\/jimmunol.168.11.5499","volume":"168","author":"B Livingston","year":"2002","unstructured":"Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, Sette A. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol. 2002;168(11):5499\u2013506.","journal-title":"J Immunol"},{"issue":"7","key":"12294_CR78","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1080\/07391102.2020.1850357","volume":"40","author":"VS Ayyagari","year":"2022","unstructured":"Ayyagari VS, Srirama TCVKAP. Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach. J Biomol Struct Dyn. 2022;40(7):2963\u201377.","journal-title":"J Biomol Struct Dyn"},{"issue":"10","key":"12294_CR79","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65(10):1357\u201369.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"12294_CR80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s43141-021-00160-z","volume":"19","author":"HB Kolla","year":"2021","unstructured":"Kolla HB, Tirumalasetty C, Sreerama K, Ayyagari VS. An immunoinformatics approach for the design of a multi-epitope vaccine targeting super antigen TSST-1 of Staphylococcus aureus. J Genet Eng Biotechnol. 2021;19(1):69.","journal-title":"J Genet Eng Biotechnol"},{"issue":"8","key":"12294_CR81","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/protein\/14.8.529","volume":"14","author":"R Arai","year":"2001","unstructured":"Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001;14(8):529\u201332.","journal-title":"Protein Eng"},{"issue":"1","key":"12294_CR82","doi-asserted-by":"crossref","first-page":"20864","DOI":"10.1038\/s41598-020-77547-4","volume":"10","author":"E Behmard","year":"2020","unstructured":"Behmard E, Soleymani B, Najafi A, Barzegari E. Immunoinformatic design of a COVID-19 subunit vaccine using entire structural Immunogenic epitopes of SARS-CoV-2. Sci Rep. 2020;10(1):20864.","journal-title":"Sci Rep"},{"key":"12294_CR83","doi-asserted-by":"crossref","first-page":"104236","DOI":"10.1016\/j.micpath.2020.104236","volume":"145","author":"P Kalita","year":"2020","unstructured":"Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020;145:104236.","journal-title":"Microb Pathog"},{"issue":"11","key":"12294_CR84","doi-asserted-by":"crossref","first-page":"e05528","DOI":"10.1016\/j.heliyon.2020.e05528","volume":"6","author":"H Singh","year":"2020","unstructured":"Singh H, Jakhar R, Sehrawat N. Designing Spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020;6(11):e05528.","journal-title":"Heliyon"},{"issue":"9","key":"12294_CR85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13205-022-03286-0","volume":"12","author":"A Kumar","year":"2022","unstructured":"Kumar A, Rathi E, Kini SG. Computational design of a broad-spectrum multi-epitope vaccine candidate against seven strains of human coronaviruses. 3 Biotech. 2022;12(9):240.","journal-title":"3 Biotech"},{"key":"12294_CR86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fimmu.2015.00115","volume":"6","author":"LR Machado","year":"2015","unstructured":"Machado LR, Ottolini B. An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses. Front Immunol. 2015;6:115.","journal-title":"Front Immunol"},{"issue":"1","key":"12294_CR87","doi-asserted-by":"crossref","first-page":"16219","DOI":"10.1038\/s41598-020-73371-y","volume":"10","author":"A Singh","year":"2020","unstructured":"Singh A, Thakur M, Sharma LK, Chandra K. Designing a multi-epitope peptide based vaccine against SARS-CoV-2. Sci Rep. 2020;10(1):16219.","journal-title":"Sci Rep"},{"issue":"1","key":"12294_CR88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41392-023-01553-x","volume":"8","author":"J Fu","year":"2023","unstructured":"Fu J, Zong X, Jin M, Min J, Wang F, Wang Y. Mechanisms and regulation of defensins in host defense. Signal Transduct Target Ther. 2023;8(1):300.","journal-title":"Signal Transduct Target Ther"},{"issue":"5595","key":"12294_CR89","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1075565","volume":"298","author":"A Biragyn","year":"2002","unstructured":"Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298(5595):1025\u20139.","journal-title":"Science"},{"issue":"8","key":"12294_CR90","doi-asserted-by":"crossref","first-page":"e104351","DOI":"10.1371\/journal.pone.0104351","volume":"9","author":"SJ Lee","year":"2014","unstructured":"Lee SJ, Shin SJ, Lee MH, Lee MG, Kang TH, Park WS, Soh BY, Park JH, Shin YK, Kim HW, et al. A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy. PLoS ONE. 2014;9(8):e104351.","journal-title":"PLoS ONE"},{"issue":"19","key":"12294_CR91","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1093\/bioinformatics\/btx345","volume":"33","author":"M Hebditch","year":"2017","unstructured":"Hebditch M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J. Protein-Sol: a web tool for predicting protein solubility from sequence. Bioinformatics. 2017;33(19):3098\u2013100.","journal-title":"Bioinformatics"},{"key":"12294_CR92","first-page":"531","volume":"112","author":"MR Wilkins","year":"1999","unstructured":"Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. Protein identification and analysis tools in the expasy server. Methods Mol Biol. 1999;112:531\u201352.","journal-title":"Methods Mol Biol"},{"key":"12294_CR93","doi-asserted-by":"crossref","unstructured":"Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 2004, 32(Web Server issue):W526\u2013531.","DOI":"10.1093\/nar\/gkh468"},{"issue":"Web Server issu","key":"12294_CR94","doi-asserted-by":"crossref","first-page":"W294","DOI":"10.1093\/nar\/gks493","volume":"40","author":"J Ko","year":"2012","unstructured":"Ko J, Park H, Heo L, Seok C. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40(Web Server issue):W294\u2013297.","journal-title":"Nucleic Acids Res"},{"key":"12294_CR95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski RA, MMW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J Appl Chrystallography. 1993;26:283\u201391.","journal-title":"J Appl Chrystallography"},{"issue":"2","key":"12294_CR96","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.virol.2009.07.001","volume":"392","author":"HS Suh","year":"2009","unstructured":"Suh HS, Zhao ML, Choi N, Belbin TJ, Brosnan CF, Lee SC. TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS. Virology. 2009;392(2):246\u201359.","journal-title":"Virology"},{"issue":"9","key":"12294_CR97","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.str.2020.06.006","volume":"28","author":"IT Desta","year":"2020","unstructured":"Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and its limits in rigid body Protein-Protein Docking. Structure. 2020;28(9):1071\u201381. e1073.","journal-title":"Structure"},{"key":"12294_CR98","doi-asserted-by":"crossref","first-page":"e07454","DOI":"10.7554\/eLife.07454","volume":"4","author":"A Vangone","year":"2015","unstructured":"Vangone A, Bonvin AM. Contacts-based prediction of binding affinity in protein-protein complexes. Elife. 2015;4:e07454.","journal-title":"Elife"},{"issue":"1","key":"12294_CR99","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pro.3289","volume":"27","author":"RA Laskowski","year":"2018","unstructured":"Laskowski RA, Jablonska J, Pravda L, Varekova RS, Thornton JM. PDBsum: structural summaries of PDB entries. Protein Sci. 2018;27(1):129\u201334.","journal-title":"Protein Sci"},{"issue":"8","key":"12294_CR100","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K Lindorff-Larsen","year":"2010","unstructured":"Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE. Improved side-chain torsion potentials for the amber ff99SB protein force field. Proteins. 2010;78(8):1950\u20138.","journal-title":"Proteins"},{"key":"12294_CR101","doi-asserted-by":"crossref","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, Lindahl E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015.","DOI":"10.1016\/j.softx.2015.06.001"},{"key":"12294_CR102","doi-asserted-by":"crossref","unstructured":"Hess B, Bekker H, Berendsen C, H. J., Fraaije M. G. E.: LINCS: A linear constraint solver for molecular simulations. J Comput Chem 1997.","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H"},{"key":"12294_CR103","doi-asserted-by":"crossref","unstructured":"Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys 1981.","DOI":"10.1063\/1.328693"},{"key":"12294_CR104","doi-asserted-by":"crossref","first-page":"1264612","DOI":"10.3389\/fmicb.2023.1264612","volume":"14","author":"W Hou","year":"2023","unstructured":"Hou W, Wu H, Wang S, Wang W, Wang B, Wang H. Designing a multi-epitope vaccine to control Porcine epidemic diarrhea virus infection using immunoinformatics approaches. Front Microbiol. 2023;14:1264612.","journal-title":"Front Microbiol"},{"key":"12294_CR105","doi-asserted-by":"crossref","first-page":"1269774","DOI":"10.3389\/fimmu.2023.1269774","volume":"14","author":"R Jyotisha, Qureshi","year":"2023","unstructured":"Jyotisha, Qureshi R, Qureshi IA. Development of a multi-epitope vaccine candidate for leishmanial parasites applying immunoinformatics and in vitro approaches. Front Immunol. 2023;14:1269774.","journal-title":"Front Immunol"},{"key":"12294_CR106","doi-asserted-by":"crossref","first-page":"1100188","DOI":"10.3389\/fimmu.2023.1100188","volume":"14","author":"F Zhu","year":"2023","unstructured":"Zhu F, Tan C, Li C, Ma S, Wen H, Yang H, Rao M, Zhang P, Peng W, Cui Y, et al. Design of a multi-epitope vaccine against six nocardia species based on reverse vaccinology combined with immunoinformatics. Front Immunol. 2023;14:1100188.","journal-title":"Front Immunol"},{"issue":"8","key":"12294_CR107","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1080\/07391102.2020.1846626","volume":"40","author":"PR Sirohi","year":"2022","unstructured":"Sirohi PR, Gupta J, Somvanshi P, Prajapati VK, Grover A. Multiple epitope-based vaccine prediction against SARS-CoV-2 Spike glycoprotein. J Biomol Struct Dyn. 2022;40(8):3347\u201358.","journal-title":"J Biomol Struct Dyn"},{"issue":"7","key":"12294_CR108","doi-asserted-by":"crossref","first-page":"102470","DOI":"10.1016\/j.jiph.2024.102470","volume":"17","author":"A Kumar","year":"2024","unstructured":"Kumar A, Dutt M, Dehury B, Martinez GS, Singh KP, Kelvin DJ. Formulation of next-generation polyvalent vaccine candidates against three important poxviruses by targeting DNA-dependent RNA polymerase using an integrated immunoinformatics and molecular modeling approach. J Infect Public Health. 2024;17(7):102470.","journal-title":"J Infect Public Health"},{"issue":"2","key":"12294_CR109","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.virusres.2013.01.009","volume":"173","author":"M Shafiq","year":"2013","unstructured":"Shafiq M, Minakshi P, Bhateja A, Ranjan K, Prasad G. Evidence of genetic reassortment between Indian isolate of bluetongue virus serotype 21 (BTV-21) and bluetongue virus serotype 16 (BTV-16. Virus Res. 2013;173(2):336\u201343.","journal-title":"Virus Res"},{"issue":"1","key":"12294_CR110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0042-6822(84)90131-4","volume":"135","author":"P Mertens","year":"1984","unstructured":"Mertens P, Brown F, Sangar D. Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology. 1984;135(1):207\u201317.","journal-title":"Virology"},{"key":"12294_CR111","doi-asserted-by":"crossref","unstructured":"Pyasi S, Sharma V, Dipti K, Jonniya NA, Nayak D. Immunoinformatics approach to design Multi-Epitope- subunit vaccine against bovine ephemeral fever disease. Vaccines (Basel) 2021, 9(8).","DOI":"10.3390\/vaccines9080925"},{"issue":"10","key":"12294_CR112","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00262-022-03181-w","volume":"71","author":"A Samad","year":"2022","unstructured":"Samad A, Meghla NS, Nain Z, Karpinski TM, Rahman MS. Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches. Cancer Immunol Immunother. 2022;71(10):2535\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"12294_CR113","doi-asserted-by":"crossref","first-page":"1259612","DOI":"10.3389\/fimmu.2023.1259612","volume":"14","author":"S Aiman","year":"2023","unstructured":"Aiman S, Ahmad A, Khan AA, Alanazi AM, Samad A, Ali SL, Li C, Ren Z, Khan A, Khattak S. Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against leishmania tropica - a hierarchical subtractive proteomics and immunoinformatics approach. Front Immunol. 2023;14:1259612.","journal-title":"Front Immunol"},{"issue":"8","key":"12294_CR114","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bpj.2014.08.033","volume":"107","author":"IA Vakser","year":"2014","unstructured":"Vakser IA. Protein-protein docking: from interaction to interactome. Biophys J. 2014;107(8):1785\u201393.","journal-title":"Biophys J"},{"key":"12294_CR115","doi-asserted-by":"crossref","unstructured":"Gajula MNV KA IJ. Protocol for Molecular Dynamics Simulations of Proteins. 2016.","DOI":"10.21769\/BioProtoc.2051"},{"key":"12294_CR116","doi-asserted-by":"crossref","unstructured":"Marin-Lopez A, Calvo-Pinilla E, Barriales D, Lorenzo G, Brun A, Anguita J, Ortego J. CD8 T cell responses to an immunodominant epitope within the nonstructural protein NS1 provide wide Immunoprotection against bluetongue virus in IFNAR(-\/-) mice. J Virol 2018, 92(16).","DOI":"10.1128\/JVI.00938-18"},{"key":"12294_CR117","doi-asserted-by":"crossref","unstructured":"Utrilla-Trigo S, Jimenez-Cabello L, Alonso-Ravelo R, Calvo-Pinilla E, Marin-Lopez A, Moreno S, Lorenzo G, Benavides J, Gilbert S, Nogales A et al. Heterologous combination of ChAdOx1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and Cross-Protective CD8\u2009+\u2009T cell immunity to bluetongue virus. Vaccines (Basel) 2020, 8(3).","DOI":"10.3390\/vaccines8030346"},{"issue":"3","key":"12294_CR118","doi-asserted-by":"crossref","first-page":"e0161421","DOI":"10.1128\/JVI.01614-21","volume":"96","author":"S Utrilla-Trigo","year":"2022","unstructured":"Utrilla-Trigo S, Jimenez-Cabello L, Calvo-Pinilla E, Marin-Lopez A, Lorenzo G, Sanchez-Cordon P, Moreno S, Benavides J, Gilbert S, Nogales A, et al. The combined expression of the nonstructural protein NS1 and the N-Terminal half of NS2 (NS2(1-180)) by ChAdOx1 and MVA confers protection against clinical disease in sheep upon bluetongue virus challenge. J Virol. 2022;96(3):e0161421.","journal-title":"J Virol"},{"issue":"11","key":"12294_CR119","doi-asserted-by":"crossref","first-page":"e111605","DOI":"10.1371\/journal.pone.0111605","volume":"9","author":"C Bouet-Cararo","year":"2014","unstructured":"Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, Viarouge C, Desprat A, Relmy A, Guibert JM, et al. Expression of VP7, a bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PLoS ONE. 2014;9(11):e111605.","journal-title":"PLoS ONE"},{"issue":"3","key":"12294_CR120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/cdli.4.3.297-301.1997","volume":"4","author":"LD Jones","year":"1997","unstructured":"Jones LD, Williams T, Bishop D, Roy P. Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection. Clin Diagn Lab Immunol. 1997;4(3):297\u2013301.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"11","key":"12294_CR121","doi-asserted-by":"crossref","first-page":"e0143273","DOI":"10.1371\/journal.pone.0143273","volume":"10","author":"V Martin","year":"2015","unstructured":"Martin V, Pascual E, Avia M, Pena L, Valcarcel F, Sevilla N. Protective efficacy in sheep of Adenovirus-Vectored vaccines against bluetongue virus is associated with specific T cell responses. PLoS ONE. 2015;10(11):e0143273.","journal-title":"PLoS ONE"},{"issue":"1","key":"12294_CR122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1297-9716-45-30","volume":"45","author":"JM Rojas","year":"2014","unstructured":"Rojas JM, Pena L, Martin V, Sevilla N. Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes. Vet Res. 2014;45(1):30.","journal-title":"Vet Res"},{"issue":"40","key":"12294_CR123","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1016\/j.vaccine.2011.07.061","volume":"29","author":"JM Rojas","year":"2011","unstructured":"Rojas JM, Rodriguez-Calvo T, Pena L, Sevilla N. T cell responses to bluetongue virus are directed against multiple and identical CD4\u2009+\u2009and CD8\u2009+\u2009T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine. 2011;29(40):6848\u201357.","journal-title":"Vaccine"},{"key":"12294_CR124","unstructured":"Harish Babu Kolla MD, Anuj Kumar RH, Nanjunadappa T, Karakach KP, Singh D, Kelvin. Peter Paul Clement Mertens, Channakeshava Sokke Umeshappa: Immuno-informatics Study Identifies Conserved T Cell Epitopes in Non-structural Proteins of Bluetongue Virus Serotypes: Formulation of Computationally Optimized Next-Generation Broad-spectrum Multiepitope Vaccine. BioRxiv 2023."},{"key":"12294_CR125","doi-asserted-by":"crossref","unstructured":"Fablet A, Kundlacz C, Dupre J, Hirchaud E, Postic L, Sailleau C, Breard E, Zientara S, Vitour D, Caignard G. Comparative virus-Host protein interactions of the bluetongue virus NS4 virulence factor. Viruses 2022, 14(2).","DOI":"10.3390\/v14020182"},{"issue":"1","key":"12294_CR126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0034-5288(18)32007-1","volume":"36","author":"MH Jeggo","year":"1984","unstructured":"Jeggo MH, Wardley RC, Taylor WP. Role of neutralising antibody in passive immunity to bluetongue infection. Res Vet Sci. 1984;36(1):81\u20136.","journal-title":"Res Vet Sci"},{"issue":"1","key":"12294_CR127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13567-017-0444-3","volume":"48","author":"JM Rojas","year":"2017","unstructured":"Rojas JM, Rodriguez-Calvo T, Sevilla N. Recall T cell responses to bluetongue virus produce a narrowing of the T cell repertoire. Vet Res. 2017;48(1):38.","journal-title":"Vet Res"},{"issue":"3","key":"12294_CR128","first-page":"403","volume":"52","author":"MH Jeggo","year":"1984","unstructured":"Jeggo MH, Wardley RC, Brownlie J. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology. 1984;52(3):403\u201310.","journal-title":"Immunology"},{"key":"12294_CR129","first-page":"258","volume":"66","author":"MH Takamatsu HaJ","year":"1989","unstructured":"Takamatsu HaJ MH. Cultivation of bluetongue Virus-Specific ovine T cells and their Cross-Reactivity with different serotype viruses. Immunology. 1989;66:258\u201363.","journal-title":"Immunology"},{"issue":"12","key":"12294_CR130","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.tips.2024.10.013","volume":"45","author":"M Shah","year":"2024","unstructured":"Shah M, Rafiq S, Woo HG. Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors. Trends Pharmacol Sci. 2024;45(12):1104\u201318.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"12294_CR131","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","volume":"13","author":"K Sargsyan","year":"2017","unstructured":"Sargsyan K, Grauffel C, Lim C. How molecular size impacts RMSD applications in molecular dynamics simulations. J Chem Theory Comput. 2017;13(4):1518\u201324.","journal-title":"J Chem Theory Comput"},{"key":"12294_CR132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-0716-3441-7_7","volume":"2714","author":"S AlRawashdeh","year":"2024","unstructured":"AlRawashdeh S, Barakat KH. Applications of molecular dynamics simulations in drug discovery. Methods Mol Biol. 2024;2714:127\u201341.","journal-title":"Methods Mol Biol"},{"key":"12294_CR133","doi-asserted-by":"crossref","first-page":"693204","DOI":"10.3389\/fmicb.2021.693204","volume":"12","author":"D Evseev","year":"2021","unstructured":"Evseev D, Magor KE. Molecular evolution of the influenza A virus Non-structural protein 1 in interspecies transmission and adaptation. Front Microbiol. 2021;12:693204.","journal-title":"Front Microbiol"},{"key":"12294_CR134","doi-asserted-by":"crossref","unstructured":"Potter BI, Kondor R, Hadfield J, Huddleston J, Barnes J, Rowe T, Guo L, Xu X, Neher RA, Bedford T, Wentworth DE. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017\u20132018 influenza season. Virus evolution 2019.","DOI":"10.1101\/543322"},{"key":"12294_CR135","unstructured":"Rijn v. Prospects of Next-Generation Vaccines for Bluetongue. Frontiers in Veterinary sciences 2019."},{"key":"12294_CR136","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Mart\u00edn DL-LA, Avia M, Mart\u00edn V, Rojas JM, Sevilla N. The interplay between bluetongue virus infections and adaptive immunity. Viruses; 2021.","DOI":"10.3390\/v13081511"},{"key":"12294_CR137","unstructured":"singh K. Haematologieal and biochemical responses in native sheep experimentally infected dth bluetongue Grus serotype. 2011."},{"issue":"3\u20134","key":"12294_CR138","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.vetmic.2010.02.033","volume":"144","author":"CS Umeshappa","year":"2010","unstructured":"Umeshappa CS, Singh KP, Nanjundappa RH, Pandey AB. Apoptosis and immuno-suppression in sheep infected with bluetongue virus serotype-23. Vet Microbiol. 2010;144(3\u20134):310\u20138.","journal-title":"Vet Microbiol"},{"issue":"9","key":"12294_CR139","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s00216-021-03806-6","volume":"414","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tang CY, Wan XF. Antigenic characterization of influenza and SARS-CoV-2 viruses. Anal Bioanal Chem. 2022;414(9):2841\u201381.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"12294_CR140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12985-022-01755-9","volume":"19","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Guo Y, Li Y, Liang B, Sun X, Li S, Xia H, Ping J. The molecular determinants of antigenic drift in a novel avian influenza A (H9N2) variant virus. Virol J. 2022;19(1):26.","journal-title":"Virol J"},{"issue":"1","key":"12294_CR141","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4049\/jimmunol.182.1.193","volume":"182","author":"CS Umeshappa","year":"2009","unstructured":"Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J. CD4\u2009+\u2009Th-APC with acquired peptide\/MHC class I and II complexes stimulate type 1 helper CD4\u2009+\u2009and central memory CD8\u2009+\u2009T cell responses. J Immunol. 2009;182(1):193\u2013206.","journal-title":"J Immunol"},{"issue":"5","key":"12294_CR142","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/icb.2011.28","volume":"89","author":"CS Umeshappa","year":"2011","unstructured":"Umeshappa CS, Xiang J. Regulators of T-cell memory generation: TCR signals versus CD4\u2009+\u2009help? Immunol Cell Biol. 2011;89(5):578\u201380.","journal-title":"Immunol Cell Biol"},{"issue":"10","key":"12294_CR143","doi-asserted-by":"crossref","first-page":"e47004","DOI":"10.1371\/journal.pone.0047004","volume":"7","author":"C Sokke Umeshappa","year":"2012","unstructured":"Sokke Umeshappa C, Hebbandi Nanjundappa R, Xie Y, Freywald A, Deng Y, Ma H, Xiang J. CD154 and IL-2 signaling of CD4\u2009+\u2009T cells play a critical role in multiple phases of CD8\u2009+\u2009CTL responses following adenovirus vaccination. PLoS ONE. 2012;7(10):e47004.","journal-title":"PLoS ONE"},{"issue":"6","key":"12294_CR144","doi-asserted-by":"crossref","first-page":"e64787","DOI":"10.1371\/journal.pone.0064787","volume":"8","author":"CS Umeshappa","year":"2013","unstructured":"Umeshappa CS, Xie Y, Xu S, Nanjundappa RH, Freywald A, Deng Y, Ma H, Xiang J. Th cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways. PLoS ONE. 2013;8(6):e64787.","journal-title":"PLoS ONE"},{"issue":"2","key":"12294_CR145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cmi.2013.59","volume":"11","author":"H Fang","year":"2014","unstructured":"Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by damps released from chemically stressed cancer cells. Cell Mol Immunol. 2014;11(2):150\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"12294_CR146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/eji.201141855","volume":"42","author":"A Pantel","year":"2012","unstructured":"Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, Brane L, Ruane D, Teixeira A, Bozzacco L, Steinman RM, et al. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol. 2012;42(1):101\u20139.","journal-title":"Eur J Immunol"}],"container-title":["BMC Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12864-025-12294-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-12294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-12294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:28:35Z","timestamp":1781648915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12864-025-12294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12294"],"URL":"https:\/\/doi.org\/10.1186\/s12864-025-12294-2","relation":{},"ISSN":["1471-2164"],"issn-type":[{"value":"1471-2164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"517"}}